2024 Napa Valley Lung Cancer Conference

Santa Rosa, CA US
May 10, 2024 to May 11, 2024

This CME-accredited activity 2024 Napa Valley Lung Cancer Conference features leading experts in thoracic malignancies who will provide a comprehensive overview of current and emerging strategies for management of lung cancer (NSCLC, SCLC). The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with lung cancer. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted-therapies for thoracic oncology. Expert faculty will aim to place the role of diagnostics, biomarkers and different therapeutic agents in clinical context and discuss how to utilize these tests and therapies to effectively contribute to patient care. 

Target Audience

  • Medical Oncologists
  • Surgeons
  • Radiation Oncologists,
  • Pathologists
  • Oncology Fellows
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists

ORGANIZING COMMITTEE

Conference Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Jonathan Riess, MD, MS - UC Davis 

Organizing Committee:

Deepti Behl, MD - Sutter Health

Ranjan Pathak, MD - Enloe Health

Heather Wakelee, MD, FASCO - Stanford University

Matthew Gubens, MD, MS - UC San Francisco

VENUE INFORMATION 

A limited number of rooms have been booked at the Hyatt Regency Sonoma Valley at a discounted nightly rate of $229 per room for this conference's attendees and sponsors. Please book your room at this link here by April 9, 2024.  

Learning Objectives

  1. Review potentially actionable molecular abnormalities in lung cancer, and the appropriate testing and treatment for actionable alteration.
  2. Summarize efficacy and toxicities of immune checkpoint inhibitors, targeted therapy, and other chemotherapy agents in management of management of lung cancer.
  3. Identify the role of perioperative systemic therapy options in curative-intent treatment of NSCLC, including the role of chemotherapy, immune checkpoint inhibitors and targeted therapy.
  4. Integrate emerging evidence of cutting edge developments in precision oncology into treatment paradigms for treatment of thoracic malignancies.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
Course opens: 
12/06/2021
Course expires: 
08/31/2024
Event starts: 
05/10/2024 - 7:00am PDT
Event ends: 
05/11/2024 - 4:00pm PDT
Cost:
$350.00

Day 1 - May 10th, 2024

All times are listed in Pacific Daylight Time (PDT)

03:00 PM - 03:30 PM  Registration, Networking, & Exhibits


03:30 PM - 03:45 PM  Opening Remarks


03:45 PM - 05:30 PM  Session 1: The Evolution of Treatment for EGFR Mutated Lung Cancer

Moderators: Jonathan Riess, MD, MS & Jennifer Marie Suga, MD

03:45 PM - 04:15 PM  Keynote Speech: Plasma Circulating Tumor DNA to Treat Lung Cancer: Current & Future Directions - David R. Gandara, MD

04:15 PM - 04:30 PM  Optimal 1L Therapy for Advanced EGFR Mutant Lung Cancer (Common Mutations) - Lei Deng, MD

04:30 PM - 04:45 PM  Targeting HER2 in NSCLC - Jennifer Marie Suga, MD

04:45 PM - 05:00 PM  EGFR Exon 20 ins and Uncommon Mutations in NSCLC - Jonathan Riess, MD, MS

05:00 PM - 05:15 PM  Overcoming EGFR TKI resistance mechanisms and Optimal 2L Treatment in EGFR mutant NSCLC - Nathaniel Myall, MD

05:15 PM - 05:30 PM  Panel Discussion


05:30 PM - 06:30 PM  Session 2: New Targets and Treatments in Oncogene Driven Lung Cancer

Moderators: Deepti Behl, MD & Claire Mulvey, MD

05:30 PM - 05:45 PM  Evolution of ALK and ROS1 Treatments in Lung Cancer - Mohana Roy, MD

05:45 PM - 06:00 PM  Targeting Uncommon Oncogene Drivers (MET, RET, and Others) - Nathaniel Myall, MD

06:00 PM - 06:15 PM  Next Generation KRAS Inhibitors - Claire Mulvey, MD

06:15 PM - 06:30 PM  Panel Discussion


06:30 PM - 07:15 PM  Reception, Networking, & Exhibits 


 

Day 2 - May 11th, 2024

07:00 AM - 08:00 AM  Breakfast & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD


08:20 AM - 09:40 AM  Session 3: Immunotherapy in Advanced Lung Cancer - What's Next? 

Moderators: Ranjan Pathak, MD & Tianhong Li, MD, PhD

08:20 AM - 08:35 AM  New Biomarkers for IO Agents in Lung Cancer - Surbhi Singhal, MD

08:35 AM - 08:50 AM  Cellular Therapies in Lung Cancer - Allison Betof Warner, MD, PhD

08:50 AM - 09:05 AM  Novel IO Agents in NSCLC- Tianhong Li, MD, PhD

09:05 AM - 09:20 AM  Advances in Treatment of Thymic Malignancies - Kavitha Ramchandran, MD

09:20 AM - 09:40 AM  Panel Discussion


09:40 AM - 11:10 AM  Session 4: Perioperative Treatment in Lung Cancer

Moderators: Heather Wakelee, MD & Sam Mazj, MD

09:40 AM - 10:10 AM  Keynote Speech: Perioperative Therapy in Lung Cancer: How Far We Have Come and Where Are We Going - Heather Wakelee, MD

10:10 AM - 10:25 AM  Neoadjuvant Chemo-IO Only - Joel Neal, MD, PhD

10:25 AM - 10:40 AM  Neoadjuvant + Adjuvant- Matthew Gubens, MD, MS, FASCO

10:40 AM - 10:55 AM  Integrating Targeted Therapy in Early Stage and Locally Advanced NSCLC- Misako Nagasaka, MD, PhD

10:55 AM - 11:10 AM  Panel Discussion


11:10 AM - 11:30 AM  Break & Exhibits


11:30 AM - 12:30 PM  Session 5: Radiation in Multimodality Therapy in Lung Cancer

Moderators: Hubert Pan, MD & Siddhartha Devarakonda, MD

11:30 AM - 11:45 AM  Is Radiation a Sensitizer to Immunotherapy in Lung Cancer?- Arta Monjazeb, MD, PhD

11:45 AM - 12:00 PM  Immunotherapy Optimization and Selection in Stage III Disease - Sue Yom, MD, PhD

12:00 PM - 12:15 PM  ctDNA for MRD Monitoring in Curative Lung Cancer - Joel Neal, MD, PhD

12:15 PM - 12:30 PM  Panel Discussion


12:30 PM - 01:30 PM  Lunch & Exhibits

12:45 PM to 01:30 PM: Product Theater Sponsored by Regeneron in Sonoma Mountain Room

Topic: IMMUNOTHERAPY IN PRACTICE: A Compelling Case-Based Discussion Examining Actual Patients with Advanced NSCLC

Speaker: Robert Weber, MD

*Non CME Activity*


01:30 PM - 02:45 PM  Session 6: Latest and Greatest in Squamous Lung Cancer, Small Cell Lung Cancer, and Management of CNS Diseases

Moderators: Shiruyeh Schokrpur, MD, PhD & Jacqueline Aredo, MD

01:30 PM - 01:45 PM  Advances in Targeting SCLC and other Neuroendocrine Tumors - Kathryn Gold, MD

01:45 PM - 02:00 PM  Management of CNS Disease and Neurologic Complications in Lung cancer - Seema Nagpal, MD

02:00 PM - 02:15 PM  New Targets in Squamous NSCLC - Shiruyeh Schokrpur, MD, PhD

02:15 PM - 02:30 PM  Panel Discussion


02:30 PM - 03:15 PM  Session 7: New Targets in Lung Cancer

Moderators: Millie Das, MD & Dron Gauchan, MD

02:30 PM - 02:45 PM  ABCs of ADCs in Lung Cancer- Millie Das, MD

02:45 PM - 03:00 PM  When Do I Use Dual Immune Checkpoint Blockade in NSCLC? - Siao-Yi Wang, MD, PhD

03:00 PM - 03:15 PM  Panel Discussion


03:15 PM  Adjourn

Hyatt Regency Sonoma Valley
170 Railroad St
Santa Rosa, CA 95401
United States

A limited number of rooms have been booked at the Hyatt Regency Sonoma Valley at a discounted nightly rate of $229 per room for this conference's attendees and sponsors. Please book your room at this link here by April 9, 2024.  

 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Jonathan Riess, MD, MS

has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with EMD Serano;.
has a financial relationship (Professional Services) with Turning Point;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Biodesix;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Independent contractor) with Genentech;.
Speaker/Topic Presenter(s)

Allison Betof Warner, MD, PhD

has a financial relationship (Professional Services) with Instil Bio;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Immatics;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with BluePath Solutions;.
has a financial relationship (Professional Services) with Lyell Immunopharma;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Iovance Biotherapeutics;.
has a financial relationship (Professional Services) with Pfizer;.

Millie Das, MD

has a financial relationship (Professional Services) with Eurofins;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Varian;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Sanofi/Genzyme;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with CellSight;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Professional Services) with Catalyst Pharmaceuticals;.

Lei Deng, MD

has a financial relationship (Other) with MJH Life Sciences;.
has a financial relationship (Travel) with MJH Life Sciences;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Bristol Meyer Squibb;.

David Gandara

has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Roche-Genentech;.
has a financial relationship (Grant Or Contract) with AstraZenica;.
has a financial relationship (Grant Or Contract) with Adagene, Inc;.
has a financial relationship (Grant Or Contract) with OncoHost;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Grant Or Contract) with Oncocyte;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Guardant Health;.

Kathryn Gold

has no relevant financial relationships to disclose at this time.

Matthew Gubens

has a financial relationship (Independent contractor) with Cardinal Health;.
has a financial relationship (Independent contractor) with iTeos;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Guardant;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Gemzyme;.
has a financial relationship (Independent contractor) with Surface;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Sanofi;.

Tianhong Li, M.D., Ph.D.

has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Grant Or Contract) with AbbVie;.

Arta Monjazeb, MD PhD

has a financial relationship (Grant Or Contract) with IO Biotech;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Transgene;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Trisalus;.

Claire Mulvey, MD

has a financial relationship (Grant Or Contract) with RayzeBio;.

Nathaniel Myall, MD

has no relevant financial relationships to disclose at this time.

Misako Nagasaka

has a financial relationship (Professional Services) with Blueprint Medicine;.
has a financial relationship (Professional Services) with EMD Serono;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Travel) with AnHeart Therapeutics;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Caris Life Sciences;.

Seema Nagpal, MD

has a financial relationship (Professional Services) with Biodexa;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Enclear;.

Joel Neal, MD, PhD

has a financial relationship (Other) with CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences CME, Medical Educator Consortium, HMP Edu;.
has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Iovance Biotherapeutics;.
has a financial relationship (Other) with Sanofi/Regeneron;.
has a financial relationship (Other) with Mirati Therapeutics;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Nektar Therapeutics;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Genentech/Roche;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Natera;.
has a financial relationship (Other) with Turning Point Therapeutics;.
has a financial relationship (Other) with Summit Therapeutics;.
has a financial relationship (Other) with Boehringer Ingelheim;.
has a financial relationship (Other) with GSK;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Eli Lilly and Company;.
has a financial relationship (Other) with Regeneron Pharmaceuticals;.
has a financial relationship (Other) with Surface Oncology;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Other) with Takeda Pharmaceuticals;.
has a financial relationship (Other) with Blueprint Pharmaceuticals;.
has a financial relationship (Other) with D2G Oncology;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Novocure;.
has a financial relationship (Other) with Adaptimmune;.

Kavitha Ramchandran, MD

has a financial relationship (Other) with Group well;.
has a financial relationship (Other) with Pathomiq;.
has a financial relationship (Other) with Curio Science;.
has a financial relationship (Other) with Varian Medical Systems -;.

Mohana Roy, MD

has a financial relationship (Financial Support) with BMS;.
has a financial relationship (Financial Support) with Regeneron Inc;.

Shiruyeh Schokrpur, M.D., Ph.D.

has no relevant financial relationships to disclose at this time.

Surbhi Singhal, MD

has a financial relationship (Other) with Meetings Events and Conference Coordinators;.
has a financial relationship (Other) with Physician Education Resource;.

Marie Suga, Co-chair, Kaiser Permanente National Lung Cancer Program Medical Director, NCAL Kaiser Permanente Oncology Clinical Trials Thoracic Medical Oncologist, Kaiser Permanente Dept of Hematology/Oncology, Vallejo, CA

has a financial relationship (Grant Or Contract) with Strata Oncology;.
has a financial relationship (Grant Or Contract) with Astrazeneca;.

Heather Wakelee, MD

has a financial relationship (Grant Or Contract) with AstraZeneca /Medimmune; Bayer; BMS; Genentech/Roche; Helsinn; Merck; SeaGen; Xcovery;.
has a financial relationship (Other) with BMS, Genentech/Roche; Merck; AstraZeneca;.
has a financial relationship (Independent contractor) with IOBiotech, Mirati;.

Siao-Yi Wang, MD, PhD

has no relevant financial relationships to disclose at this time.

Sue Yom, MD, PhD

has a financial relationship (Grant Or Contract) with Nanobiostix;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
Moderator(s)

Jacqueline Aredo, MD, MS

has a financial relationship (Grant Or Contract) with AstraZeneca;.

DEEPTI BEHL, M.D.

has a financial relationship (Professional Services) with janssen;.
has a financial relationship (Professional Services) with AZ;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with boehringer;.
has a financial relationship (Professional Services) with Novartis;.

Millie Das, MD

has a financial relationship (Professional Services) with Eurofins;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Varian;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Sanofi/Genzyme;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with CellSight;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Professional Services) with Catalyst Pharmaceuticals;.

Siddhartha Devarakonda, MBBS, MD

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Eli Lilly;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Apollomics;.
has a financial relationship (Other) with Jazz;.
has a financial relationship (Other) with Daiichi-Sankyo;.

Dron Gauchan

has no relevant financial relationships to disclose at this time.

Tianhong Li, M.D., Ph.D.

has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Grant Or Contract) with Astellas;.

Sam Mazj

has no relevant financial relationships to disclose at this time.

Claire Mulvey, MD

has a financial relationship (Grant Or Contract) with RayzeBio;.

Hubert Pan, MD

has no relevant financial relationships to disclose at this time.

Ranjan Pathak

has no relevant financial relationships to disclose at this time.

Shiruyeh Schokrpur, M.D., Ph.D.

has no relevant financial relationships to disclose at this time.

Marie Suga, Co-chair, Kaiser Permanente National Lung Cancer Program Medical Director, NCAL Kaiser Permanente Oncology Clinical Trials Thoracic Medical Oncologist, Kaiser Permanente Dept of Hematology/Oncology, Vallejo, CA

has a financial relationship (Grant Or Contract) with Astrazeneca;.
has a financial relationship (Grant Or Contract) with Strata Oncology;.

Heather Wakelee, MD

has a financial relationship (Independent contractor) with IOBiotech, Mirati;.
has a financial relationship (Grant Or Contract) with AstraZeneca /Medimmune; Bayer; BMS; Genentech/Roche; Helsinn; Merck; SeaGen; Xcovery;.
has a financial relationship (Other) with BMS, Genentech/Roche; Merck; AstraZeneca;.
Planning committee(s)

DEEPTI BEHL, M.D.

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with boehringer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AZ;.
has a financial relationship (Professional Services) with janssen;.

Ranjan Pathak

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.